Glucotrack, inc. announces closing of $10.0 million public offering and concurrent private placement converting $4.0 in outstanding debt

Rutherford, nj., nov. 14, 2024 (globe newswire) -- glucotrack, inc. (nasdaq: gctk), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the closing of a “best efforts” public offering of 2,437,340 shares of common stock and 4,756,900 pre-funded warrants, with each share of common stock and each pre-funded warrant accompanied by (i) a series a common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share and (ii) a series b common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share. the combined offering price of each share of common stock together with the accompanying series a and series b common warrants is $1.39, and the combined offering price of each pre-funded warrant together with the accompanying series a and series b common warrants is $1.389. the gross proceeds of the public offering were approximately $10 million before deducting placement agent fees and offering expenses.
GCTK Ratings Summary
GCTK Quant Ranking